[Healthcare relevant data from an interdisciplinary consultation for endocrine orbitopathy].
Versorgungsrelevante Daten einer interdisziplinären Sprechstunde für endokrine Orbitopathie.
Endocrine orbitopathy
Epidemiology
Graves’ disease
Healthcare research
Interdisciplinary orbit center
Journal
Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
ISSN: 1433-0423
Titre abrégé: Ophthalmologe
Pays: Germany
ID NLM: 9206148
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
pubmed:
9
2
2020
medline:
21
11
2020
entrez:
9
2
2020
Statut:
ppublish
Résumé
Endocrine orbitopathy (EO) encompasses functional and cosmetic limitations. The aim of this study was to assess the health services situation of patients with EO treated at a multidisciplinary specialized center. The medical records pertaining to the clinical spectrum, access route, and medical specialty of the referring physician of patients who were treated within a period of 5 years at a tertiary referral orbit center were systematically assessed. A total of 431 subjects with EO (female n =354, 82%; median age 40 years, range 5-79 years) were included in the study. Of the patients 148 (35%) and 123 (29%) were referred by family physicians and ophthalmologists, respectively. A sight-threatening optic nerve neuropathy was present in 11 (14.3%) men and 21 (5.9%) women (p =0.011). At least 2 other autoimmune diseases were found in 8 (10.4%) men and in 15 (4.3%) women (p =0.079). Psychotherapeutic support was utilized by 2 (2.6%) men and 92 (26%) women (p <0.001). An access route of 50 km or more was accepted by 14 (28%) men and 83 (43%) women (p =0.054). There was also an association between an access route ≥100 km and a prior medical treatment (odds ratio 3.78, 95% confidence interval 1.18-12.05, p =0.025). Men were more severely affected by EO than women and often had complex autoimmune diseases; however, male patients were less frequently willing to accept long access routes and barely used psychosocial support. Especially patients with further autoimmune diseases travelled long distances to be treated at a specialized center.
Sections du résumé
BACKGROUND
BACKGROUND
Endocrine orbitopathy (EO) encompasses functional and cosmetic limitations. The aim of this study was to assess the health services situation of patients with EO treated at a multidisciplinary specialized center.
METHODS
METHODS
The medical records pertaining to the clinical spectrum, access route, and medical specialty of the referring physician of patients who were treated within a period of 5 years at a tertiary referral orbit center were systematically assessed.
RESULTS
RESULTS
A total of 431 subjects with EO (female n =354, 82%; median age 40 years, range 5-79 years) were included in the study. Of the patients 148 (35%) and 123 (29%) were referred by family physicians and ophthalmologists, respectively. A sight-threatening optic nerve neuropathy was present in 11 (14.3%) men and 21 (5.9%) women (p =0.011). At least 2 other autoimmune diseases were found in 8 (10.4%) men and in 15 (4.3%) women (p =0.079). Psychotherapeutic support was utilized by 2 (2.6%) men and 92 (26%) women (p <0.001). An access route of 50 km or more was accepted by 14 (28%) men and 83 (43%) women (p =0.054). There was also an association between an access route ≥100 km and a prior medical treatment (odds ratio 3.78, 95% confidence interval 1.18-12.05, p =0.025).
CONCLUSION
CONCLUSIONS
Men were more severely affected by EO than women and often had complex autoimmune diseases; however, male patients were less frequently willing to accept long access routes and barely used psychosocial support. Especially patients with further autoimmune diseases travelled long distances to be treated at a specialized center.
Identifiants
pubmed: 32034469
doi: 10.1007/s00347-020-01050-4
pii: 10.1007/s00347-020-01050-4
pmc: PMC7644527
doi:
Types de publication
Journal Article
Langues
ger
Sous-ensembles de citation
IM
Pagination
1105-1111Références
J Clin Endocrinol Metab. 2013 Apr;98(4):1443-9
pubmed: 23408569
Thyroid. 2015 Aug;25(8):942-8
pubmed: 26244413
Clin Exp Immunol. 2014 Oct;178(1):57-64
pubmed: 24903731
Am J Ophthalmol. 2011 Sep;152(3):483-490.e1
pubmed: 21676374
Pediatr Endocrinol Rev. 2010 Mar;7 Suppl 2:250-3
pubmed: 20467372
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):359-70
pubmed: 22632371
Orphanet J Rare Dis. 2017 Apr 20;12(1):72
pubmed: 28427469
Ophthalmology. 2011 Nov;118(11):2279-85
pubmed: 21684605
J Clin Endocrinol Metab. 2015 Dec;100(12):E1523-30
pubmed: 26451909
J Clin Endocrinol Metab. 2013 Jan;98(1):145-52
pubmed: 23185037
Gesundheitswesen. 2009 Oct;71(10):685-93
pubmed: 19806536
J Clin Endocrinol Metab. 2005 Sep;90(9):5234-40
pubmed: 15998777
Lancet Diabetes Endocrinol. 2018 Apr;6(4):287-298
pubmed: 29396246
Br J Ophthalmol. 2009 Aug;93(8):1052-6
pubmed: 19221109
Thyroid. 2010 Jul;20(7):777-83
pubmed: 20578901
N Engl J Med. 2011 May 19;364(20):1920-31
pubmed: 21591944
N Engl J Med. 2017 May 4;376(18):1748-1761
pubmed: 28467880
Pediatr Endocrinol Rev. 2010 Mar;7 Suppl 2:245-9
pubmed: 20467371
J Endocrinol Invest. 2015 Jul;38(7):769-77
pubmed: 25736545
Med Klin (Munich). 2008 Oct 15;103(10):717-30; quiz 729-30
pubmed: 18936897
Ophthalmologe. 2016 Feb;113(2):126-30
pubmed: 26801325
J Clin Endocrinol Metab. 2010 May;95(5):2123-31
pubmed: 20237164
Klin Monbl Augenheilkd. 2009 Feb;226(2):R13-28; quiz R29-31
pubmed: 19206039
Br J Ophthalmol. 2015 Nov;99(11):1531-5
pubmed: 25953846
Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2649-56
pubmed: 25829418
Eur J Endocrinol. 2008 Mar;158(3):273-85
pubmed: 18299459
Ophthalmologe. 2016 Apr;113(4):349-64; quiz 465-6
pubmed: 27059986
Eur J Endocrinol. 2006 Sep;155(3):387-9
pubmed: 16914591
Eur Thyroid J. 2016 Mar;5(1):9-26
pubmed: 27099835
Orbit. 2005 Sep;24(3):165-71
pubmed: 16169801
Dtsch Arztebl Int. 2009 Apr;106(17):283-9
pubmed: 19547630
Clin Endocrinol (Oxf). 2005 Oct;63(4):395-402
pubmed: 16181231
Dtsch Med Wochenschr. 1997 Jan 3;122(1-2):27-32
pubmed: 9064230